- Home
- SDSTW vs APRE Comparison
SDSTW vs APRE Comparison
Compare SDSTW & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDSTW | APRE |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 8.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SDSTW | APRE |
|---|---|---|
| Price | $0.16 | $0.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 7.0K | ★ 308.7K |
| Earning Date | 03-26-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.55 |
| 52 Week High | $0.30 | $2.22 |
Technical Indicators
Market Signals| Indicator | SDSTW | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 41.66 | 57.86 |
| Support Level | $0.10 | $0.57 |
| Resistance Level | $0.22 | $0.98 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 22.40 | 66.84 |
Price Performance
Historical ComparisonAbout SDSTW Stardust Power Inc. Warrant
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.